DEBORAH WHATLEY: Open Payments
NPI 1184110900 · LEXINGTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,087 in 219 payments from 14 companies in 2025. Trend: 2023 $2,697 · 2024 $2,833 · 2025 $3,087
Food & beverage: $3,087
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 47 | $444 |
| Neurocrine BioSciences, Inc. | 36 | $420 |
| ABBVIE INC. | 40 | $385 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $379 |
| E.R. Squibb & Sons, L.L.C. | 17 | $306 |
| Alkermes, Inc. | 14 | $266 |
| Otsuka America Pharmaceutical, Inc. | 17 | $260 |
| Janssen Pharmaceuticals, Inc | 6 | $234 |
| Vanda Pharmaceuticals Inc. | 11 | $168 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, COBENFY, AUSTEDO XR, ARISTADA, INVEGA SUSTENNA, UZEDY.
Industry payments across SC — which companies pay providers there.
